MECHANISM OF DELIVERY

How Vyvanse is
delivered within
the body

Hypothetical patient portrayal.
Individual results may vary.

Prodrug Formulation

Prodrug formulation

Lisdexamfetamine is a prodrug of dextroamphetamine.1 In general, prodrugs are pharmacologically inert chemical derivatives that are converted in vivo into active drug molecules.2

The clinical relevance of the prodrug formulation has not been established. 

Vyvanse® in the GI tract

GI Tract

After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal (GI) tract.3

Vyvanse® in circulation

In Circulation

Lisdexamfetamine is converted to dextroamphetamine and l-lysine primarily in the blood. This occurs due to the hydrolytic activity of red blood cells.1

The conversion of lisdexamfetamine in the blood produces dextroamphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulant activity.1

Vyvanse® in the central nervous system (CNS)

In CNS

Amphetamines block the reuptake of catecholamines norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.1

The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.1

The clinical significance of in vitro data is unknown.

The mode of therapeutic action in ADHD is not known.1

HOW VYVANSE IS DELIVERED THE BODY

Proven efficacy in adults.

Hypothetical patient portrayal.
Individual results may vary.

EFFICACY STUDIES FOR
ADHD IN ADULTS

Vyvanse (lisdexamfetamine dimesylate) is a CNS stimulant used to treat ADHD in adults. Learn more about Vyvanse and the efficacy and safety data by clicking on the links below.

Proven efficacy in children.

Hypothetical patient portrayal.
Individual results may vary.

WHY VYVANSE FOR
ADHD IN CHILDREN (6-17)

Review efficacy and safety data for ADHD in children (aged 6-17) and learn more about Vyvanse.

References
  1. Vyvanse [package insert]. Lexington, MA: Shire US Inc.
  2. Han H-K, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000;2(1):45-58.
  3. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28(12):745-755.

INDICATION AND IMPORTANT SAFETY INFORMATION